Salvage radical prostatectomy for radiorecurrent prostate cancer: Is this a viable option?

Current Opinion in Urology

Volumn 10, Issue 3, 2000, Pages 229-232

  Steinberg, Gary D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLONE; GENE MUTATION; HUMAN; MALE; MORBIDITY; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; RECURRENT CANCER; REVIEW; TREATMENT OUTCOME;

DNA, NEOPLASM; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034021805     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200005000-00008     Document Type: Review

References (13)

1. 1 Zeitman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation in the management of prostatic adenocarcinoma: the initial prostate specific antigen as a predictor of treatment outcome. J Urol 1994; 151:640-645.
2. 2 Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long term results in patients treated with 1-125 implantation. Int J Rad Oncol Biol Phys 1991; 21:537-547.
3. 3 Pontes JE, Montie J, Klein E, Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer 1993; 71:976-980.
4. 4 Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CPN, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997; 157:921-925.
5. 5 Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995; 153:104-110.
6. 6 Younes E, Haas GP, Montie JE, Smith JB, Powell IJ, Pontes JE. Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy. Urology 1994; 43:22-25.
7. 7 Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999; 161:857-863. This article details prognostic factors of radiation resistant prostate cancer.
8. 8 Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999, 162:398-402.
9. 9 Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570-579.
10. 10 Scherr DS, Vaughn ED, Wei J, Chung M, Felsen D, Allbright R, Knudsen BS. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999; 162:12-17. This article assesses P53 and Bcl-2 as prognostic factors in radiorecurrent/ resistant prostate cancer.
11. 11 Bauer JJ, Sesterhann IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated localized prostate cancer. J Urol 1996; 156:1511-1516.
12. 12 Rakozy C, Grignon DJ, Li YW, Gheiler E, Gururajanna B, Pontes JE, et al. P53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. Pathol Res Pract 1999; 195:129-135.
13. 13 Cheng L, Sebo TJ, Cheville JC, PisanskyTM, Slezak J, Bergstralh EJ, et al. P53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer 1999; 85:1293-1299. This article discusses possible mechanisms of radiation resistance.